Novo’s year of obesity

Novo Nordisk is set to deliver six clinical readouts in obesity in 2020. If successful, they could deliver Novo an opportunity to dramatically expand a mostly untapped market that could become a major future growth driver for the company.

Novo is trying to deliver change in obesity, an indication that’s proven harder to crack than it should be, given the amount of biology known and the significant patient population. ...